Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin Chemotherapy
Description: 

Assess the DLTs and define the Phase 2 dose of G1T28 administered with E/P therapy. Assess the safety and tolerability of G1T28
administered with E/P therapy.

Study Number: 

PH 278815

Phase: 
Early Phase
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02499770

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.